EMERGING NEWS 

Zoom and Slack are Worth Nearly $50 Billion More Since Coronavirus hit, and Now We See the Results

By now, most of you have heard of the Coronavirus. The first cases of Coronavirus were detected in 2014 in two Pakistanis. In September 2015, a doctor and a relative of the doctor fell sick, but their conditions proved to be unrelated. In October 2015, one more person tested positive, and since then, the virus has claimed at least 74 lives.

What is Coronavirus?

It is commonly known as the coronavirus. Coronavirus is one of a large collection of viruses known as family members. It belongs to the coronavirus family of viruses. It was first identified in 1968 and is caused by a coronavirus variant known as NCoV. NCoV is the family’s most severe type.

Coronavirus causes serious illness in people who are extremely young or old. It has been shown to be capable of causing pneumonia and respiratory distress in the elderly, but the younger the person the less likely it is to cause a serious illness.

In particular, the virus is particularly serious in children, especially those younger than five years old. Rates of acute pneumonia and respiratory failure in children under five years old are extremely high in people who have contracted NCoV.

What do we know about NCoV?

We know quite a bit about NCoV – we know for example, that NCoV is the very worst type of coronavirus, it is more common and more virulent than the other types. We also know the virus is even more dangerous in children.

We also know that coronaviruses infect different tissues in the body and that they are multiple. The corona virus types are related to one another and they host different immune defences. Most people with a warm-season mosquito bite from NCoV don’t develop symptoms but they can develop respiratory problems. NCoV circulates mostly in the tropics and subtropics so it is endemic to most of the world’s population.

What can we do about NCoV?

We know that a vaccine or antiviral treatment is available. NCoV vaccine candidate is currently being developed in South Korea. A 2017 viral informatics trial in Korea found an antiviral in combination with a nasal spray could reduce severe cases of NCoV. A recent NCoV antiviral trial in Germany demonstrated efficacy of a combination of two antivirals.

What can we do now about NCoV?

Clearly, NCoV is an important public health issue. Public health resources must be deployed to prevent these infections.

While the presence of NCoV has largely been concentrated in the tropics and subtropics, the virus is still present in the WHO Europe Southern equatorial region and it has recently been discovered in the WHO Americas Northern and Central region. The WHO Europe Southern equatorial region is the home of the largest Coronavirus cluster outside of Pakistan and the incubator of many of the recent virus outbreaks in Europe.

Related posts

Leave a Comment